\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ hormone\\ therapy\\ and\\ steroids\ \(0\)\
\-\ \\â\\€\\¢\\ sclerotic\\ metastatic\\ lesions\\ to\\ left\\ frontal\\ bone\\.\ \(0\)\
\-\ \\â\\€\\¢\\ marked\\ dural\\ thickening\\ with\\ underlyning\\ brain\\ edema\\,\\ most\\ pronounced\\ in\\ the\\ left\\ frontal\\ region\\ underlying\\ the\\ bony\\ metastatic\\ deposit\\.\ \(0\)\
\-\ \\â\\€\\¢\\ hemorrhagic\\ metastatic\\ lesion\\ right\\ occipital\\ lobe\\.\ \(0\)\
\-\ dural\\ metastases\\,\\ prostate\\ cancer\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ cancer\\ \\(prostate\\)\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ atypical\\ or\\ malignant\\ meningioma\ \(0\)\
\-\ \\â\\€\\¢\\ hemangiopericytoma\ \(1\)\
\-\ 65\\ year\\ old\\ male\\ with\\ urinary\\ retention\\ and\\ headache\\.\ \(1\)\
\-\ this\\ man\\ has\\ a\\ prostate\\ cancer\\ \\-\\ a\\ piece\\ of\\ history\\ that\\ was\\ originally\\ witheld\\.\\ \\ he\\ has\\ multiple\\ skeletal\\ metastatic\\ lesions\\ including\\ calvarial\\ involvement\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ prostate\\:\\ 0\\.37334881703225975\ \(0\)\
\-\ metastatic\\:\\ 0\\.3523377580325297\ \(0\)\
\-\ cancer\\:\\ 0\\.2567401258064404\ \(0\)\
\-\ dural\\:\\ 0\\.2280361250647682\ \(0\)\
\-\ underlyning\\:\\ 0\\.2054753593245271\ \(0\)\
\-\ witheld\\:\\ 0\\.17725816373224898\ \(0\)\
\-\ deposit\\:\\ 0\\.16707766433835664\ \(0\)\
\-\ frontal\\:\\ 0\\.1653926648217928\ \(0\)\
\-\ piece\\:\\ 0\\.16009174401987078\ \(0\)\
\-\ calvarial\\:\\ 0\\.1586380803021745\ \(0\)\
\-\ retention\\:\\ 0\\.15046400782839747\ \(0\)\
\-\ lesions\\:\\ 0\\.14758069481729894\ \(0\)\
\-\ pronounced\\:\\ 0\\.14374076069161135\ \(0\)\
\-\ hemangiopericytoma\\:\\ 0\\.13637062687693133\ \(0\)\
\-\ hormone\\:\\ 0\\.13082673298833028\ \(0\)\
\-\ originally\\:\\ 0\\.13082673298833028\ \(0\)\
\-\ has\\:\\ 0\\.11737633600784363\ \(0\)\
\-\ skeletal\\:\\ 0\\.1164776641149686\ \(0\)\
\-\ steroids\\:\\ 0\\.11288215949528789\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.11145158544651068\ \(0\)\
\-\ urinary\\:\\ 0\\.111107701361374\ \(0\)\
\-\ occipital\\:\\ 0\\.10994384254303223\ \(0\)\
\-\ 65\\:\\ 0\\.10994384254303223\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.10883717933663571\ \(0\)\
\-\ sclerotic\\:\\ 0\\.10778235254476946\ \(0\)\
\-\ atypical\\:\\ 0\\.10540921544478729\ \(0\)\
\-\ underlying\\:\\ 0\\.10488537857775411\ \(0\)\
\-\ metastases\\:\\ 0\\.10387289486347467\ \(0\)\
\-\ bony\\:\\ 0\\.09899581764285391\ \(0\)\
\-\ marked\\:\\ 0\\.09717761044916028\ \(0\)\
\-\ meningioma\\:\\ 0\\.0962765314901573\ \(0\)\
\-\ involvement\\:\\ 0\\.092994523017997\ \(0\)\
\-\ including\\:\\ 0\\.09195017841163435\ \(0\)\
\-\ malignant\\:\\ 0\\.09158863019850043\ \(0\)\
\-\ headache\\:\\ 0\\.08857200834488958\ \(0\)\
\-\ left\\:\\ 0\\.08765801736211054\ \(0\)\
\-\ thickening\\:\\ 0\\.0874104065052222\ \(0\)\
\-\ brain\\:\\ 0\\.08009716019251527\ \(0\)\
\-\ region\\:\\ 0\\.07685387216624678\ \(0\)\
\-\ edema\\:\\ 0\\.07663122814526153\ \(0\)\
\-\ he\\:\\ 0\\.07608406026520591\ \(0\)\
\-\ lobe\\:\\ 0\\.07425070734743973\ \(0\)\
\-\ therapy\\:\\ 0\\.07382292003913893\ \(0\)\
\-\ bone\\:\\ 0\\.07010537730890516\ \(0\)\
\-\ man\\:\\ 0\\.06802151226168929\ \(0\)\
\-\ most\\:\\ 0\\.0668674433998208\ \(0\)\
\-\ multiple\\:\\ 0\\.06284477102440388\ \(0\)\
\-\ lesion\\:\\ 0\\.06159852917493191\ \(0\)\
\-\ male\\:\\ 0\\.05720642925585803\ \(0\)\
\-\ that\\:\\ 0\\.05575763716574817\ \(0\)\
\-\ and\\:\\ 0\\.053099671623173646\ \(0\)\
\-\ the\\:\\ 0\\.05127479454571573\ \(0\)\
\-\ with\\:\\ 0\\.050317907513800386\ \(0\)\
\-\ history\\:\\ 0\\.04908867776326398\ \(0\)\
\-\ was\\:\\ 0\\.044778266897404606\ \(0\)\
\-\ or\\:\\ 0\\.044697616033226854\ \(0\)\
\-\ this\\:\\ 0\\.04414973254992235\ \(0\)\
\-\ right\\:\\ 0\\.0425980673575705\ \(0\)\
\-\ year\\:\\ 0\\.03959652288401037\ \(0\)\
\-\ old\\:\\ 0\\.038026368645199024\ \(0\)\
\-\ to\\:\\ 0\\.03212097777268894\ \(0\)\
\-\ in\\:\\ 0\\.0319628783866166\ \(0\)\
\-\ of\\:\\ 0\\.025143930264558585\ \(0\)\
